Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. probiotears

PROBIOTEARS SIGNED

Probiotic-based Ophtalmologic treatment for Bacterial and Allergic Conjunctivitis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 PROBIOTEARS project word cloud

Explore the words cloud of the PROBIOTEARS project. It provides you a very rough idea of what is the project "PROBIOTEARS" about.

aligned    industrial    scaling    presented    market    deeper    antagonism    generate    worldwide    carry    ready    vitro    ipr    pathogens    regulatory    ophthalmologists    safety    innovative    inflammatory    galenic    ophthalmic    covered    innovation    toxicity    animal    models    vivo    feasibility    resistance    clinical    industry    broad    anti    solid    drugs    allergic    competitor    antibiotic    global    ointments    ebitda    company    treatments    intraocular    recurrent    pressure    probiotics    biotics    dimension    antihistaminic    bacterial    faster    eye    probiotic    drops    issue    million    expertise    organisms    stable    trials    strategy    health    rising    associations    formulation    histaminic    solution    formula    infections    reinforce    14m    ocular    suitable    reestablishment    microbiota    strain    people    supportive    1100    strains    micro    resistances    functional    probiotears    ab    fast    validated    live    pharmaceutical    ingredients    mainly    tests    perform    conjunctivitis    healthy    pathogenic    avoidance    protection    risks    undesired   

Project "PROBIOTEARS" data sheet

The following table provides information about the project.

Coordinator		 AB BIOTICS SA 

Organization address
address: CALLE PARC DE RECERCA UAB CAMPUS AUB EDIFICIO DESPACHO P2M1 BELLATERRA
city: CERDANYOLA DEL VALLES
postcode: 8193
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.ab-biotics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy)
2. H2020-EU.3.2.1. (Sustainable agriculture and forestry)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AB BIOTICS SA ES (CERDANYOLA DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Conjunctivitis is a major health issue affecting more than 1100 million people worldwide. Currently, the market for bacterial & allergic conjunctivitis is mainly covered by antibiotic eye drops and ointments, which have undesired effects in the eye microbiota and contribute to increase the resistances of pathogenic strains. Other treatments such as anti-inflammatory and antihistaminic drugs have also undesired side effects and are not useful as an immediate solution.

AB-BIOTICS, a company with a broad expertise in developing functional ingredients for the pharmaceutical industry, has developed an innovative solution based on the use of probiotics. Probiotics are live micro-organisms allowing a fast and stable reestablishment of a healthy eye microbiota by providing: (1) faster anti-inflammatory and anti-histaminic effects; (2) antagonism to pathogens with no resistance risks; (3) protection against future/recurrent infections; and (4) avoidance of common side effects such as intraocular pressure rising.

The effects of the selected probiotic strains have been validated through functional in vitro and in vivo tests and its safety for ocular application has also been assessed in toxicity trials in animal models. The industrial scaling up of the strain has already been achieved and is now ready for galenic formulation.

In order to determine the key steps to bring PROBIOTEARS to the market within the next 2 years, the objectives of the presented feasibility study are: • Assess clinical ophthalmologists & users associations interest • Determine the most suitable formula for ophthalmic use • Define IPR strategy • Perform a deeper market & competitor analysis • Find key partners to carry out Supportive Clinical Trials in phase 2 • Assess Regulatory Requirements

PROBIOTEARS is a solid high-potential innovation project aligned with AB-BIOTICS’ strategy which is expected to reinforce its European & global dimension, and generate an EBITDA of 2,14M€.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROBIOTEARS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROBIOTEARS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.2.4.;H2020-EU.3.2.1.;H2020-EU.2.3.1.;H2020-EU.3.2.2.)

Stoock (2018)

An Innovative Integrated Field Sensor system providing a precise farming tool to reduce productioncosts and water wastage.

Read More  

FucoPol (2017)

An innovative bio-based platform for the cost-competitive production of L-fucose, a building block for Human Milk Oligosaccharides (HMOs).

Read More  

KEEP-IT-UP (2018)

KEEP-IT-UP: Redefining shelf life monitoring in the global food industry with a new intelligent Time-Temperature Indicator for perishable products

Read More